Phaseline

Companies › NeuShen Therapeutics

NeuShen Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Other; next expected readout Feb 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
NS-079–Phase 1Healthy Adult ParticipantsFeb 2027
NS-136–Phase 1Healthy Subjects–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06345703NS-136Phase 1Healthy SubjectsOtherNov 2024
NCT07669571NS-079Phase 1Healthy Adult ParticipantsOtherFeb 2027

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.